Skip to content
PaperFren

Do gabapentinoids track with later dementia?

Open paper intelligence

Among 206,802 Taiwanese adults, gabapentin or pregabalin use was linked to higher dementia incidence (980 vs 605 per 100,000 person-years; aHR 1.45), with aHR 3.16 under age 50 and a cumulative-dose gradient.

Source

The association between Gabapentin or Pregabalin use and the risk of dementia: an analysis of the National Health Insurance Research Database in Taiwan

Huang YH, Pan MH, Yang HI · Frontiers in pharmacology · 2023

doi.org/10.3389/fphar.2023.1128601Read the full paper ↗21 citationscc by

Study at a glance

Design
Cohort — Retrospective Taiwan NHIRD/LHID 2000–2017 matched cohort of gabapentin or pregabalin users vs 1:5 propensity-matched non-users
N
N=206802 · 34,467 exposed and 172,335 unexposed adults from a 2-million-person 2005 LHID sample
Population
Taiwanese adults in the National Health Insurance Research Database who did or did not receive gabapentin or pregabalin
Outcome
Incident dementia (incidence per 100,000 person-years; adjusted HR, including age and cumulative dose strata)

Structured fields used in claim comparison tables when every cited study has a complete layer.

What they did

Built a 2000–2017 LHID cohort from 2 million NHIRD enrollees, compared 34,467 gabapentin/pregabalin users with 172,335 non-users matched 1:5 on age, sex, and index date, and estimated multivariate hazard ratios for dementia, including dose and age strata.

What they found

Dementia incidence was 980.60 vs 605.48 per 100,000 person-years. Adjusted HR 1.45 (1.36–1.55). Risk rose with cumulative defined daily doses and was significant in all ages, but higher in patients <50 (HR 3.16; 2.23–4.47).

The limits

What it doesn't show

Claims matching cannot prove gabapentinoids cause dementia; confounding by pain, epilepsy, or psychiatric comorbidity remains, and results are from one insurance system.

Key terms

Gabapentin/pregabalin
GABA-analog anticonvulsants/neuropathic-pain drugs that bind α2δ calcium channels.
NHIRD/LHID
Taiwan insurance claims; 2005 LHID is a 2-million-person random NHIRD sample.
Propensity matching
1:5 matching on age, sex, and index date for unexposed comparators.
Adjusted hazard ratio
Multivariable Cox HR; 1.45 for dementia in exposed vs matched unexposed.
cDDD
Cumulative defined daily dose; higher cumulative exposure tracked higher dementia risk.
Incidence rate
980.60 vs 605.48 dementia cases per 100,000 person-years.

Flashcards

1 / 10

Research intelligence for this paper

See its role on concept claims, tensions it is part of, placement history, and related discoveries.

Open paper intelligence

Quiz yourself

1 / 5

Analyzed N was about:

Common questions

How large was the analyzed cohort?

206,802 patients (34,467 exposed; 172,335 unexposed).

What was the adjusted HR?

1.45 (95% CI 1.36–1.55).

Who had the largest relative risk?

Younger patients (age <50), HR 3.16.

Did dose matter?

Yes—risk increased with higher cumulative defined daily doses.

More on Depression treatment